Evidence map›Paper›PMID 42613451›Full record

ReviewExperimental & molecular medicine2026

The interplay between lipid metabolism, cancer progression and anti-cancer immunity.

Choong-Hyun Koh, Yoosun Lee, Il-Kyu Kim, Yeonseok Chung

Abstract readReview
In one paragraph

Review in Experimental & molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Choong-Hyun Koh *Laboratory of Immune Regulation, Research Institute of Pharmaceutical Sciences, Seoul, South Korea.ORCID http://orcid.org/0000-0003-3342-6350
Yoosun Lee *Laboratory of Immune Regulation, Research Institute of Pharmaceutical Sciences, Seoul, South Korea.
Il-Kyu KimLaboratory of Immune Regulation, Research Institute of Pharmaceutical Sciences, Seoul, South Korea. ikkim@gachon.ac.kr.
Yeonseok ChungLaboratory of Immune Regulation, Research Institute of Pharmaceutical Sciences, Seoul, South Korea. yeonseok@snu.ac.kr.ORCID http://orcid.org/0000-0001-5780-4841

Funding

National Research Foundation of Korea (NRF) 2022R1A6A1A03046247National Research Foundation of Korea (NRF) RS-2020-NR049403National Research Foundation of Korea (NRF) RS-2024-00432867National Research Foundation of Korea (NRF) RS-2024-00444468
6 · The paper itself

Abstract

The tumour microenvironment (TME) consists of a complex ecosystem of tumour cells, stromal elements, extracellular matrix, fibroblasts and diverse immune-cell populations. Although traditional cancer therapies have primarily focused on eliminating tumour cells, subsequent advances highlighted the importance of modulating immune cells within the TME to enhance anti-tumour immunity. More recently, a major conceptual shift has emerged: targeting nutrient metabolism as a therapeutic strategy. Because tumours create a hypoglycaemic, metabolically restrictive niche, both cancer cells and infiltrating immune cells increasingly rely on lipid uptake, storage and catabolism to sustain their survival and function. This metabolic dependency reveals new vulnerabilities that can be exploited for cancer therapy. In this review, we integrate fundamental concepts of lipid metabolism with recent mechanistic discoveries that define how lipids shape cellular behaviours within the TME, emphasizing the dual roles of lipids as both metabolic substrates and signalling mediators. We also highlight emerging evidence demonstrating that dietary lipid composition - beyond total fat intake - profoundly influences tumour progression and anti-tumour immunity. Together, these insights position lipid metabolism as a critical regulator of tumour biology and an attractive target for next-generation cancer therapies.

Indexed as

Lipid MetabolismNeoplasmsAnimalsDisease ProgressionHumansSignal TransductionTumor Microenvironment

Identifiers

PMID42613451
PMCPMC13538388

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.